Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
| ▸ | IDH1 | O75874 | 6/20 | 0.44 |
| ▸ | OGA | O60502 | 2/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581673 | 1.00 | NUDT1 (0.45) | NUDT1IDH1OGANR3C2CXCR4 | |
| SCHEMBL4580725 | 0.85 | IDH1 (0.46) | NUDT1IDH1OGANR3C2HDAC6 | |
| SCHEMBL4580722 | 0.85 | IDH1 (0.46) | NUDT1IDH1OGANR3C2HDAC6 | |
| SCHEMBL4582798 | 0.85 | IDH1 (0.46) | NUDT1IDH1OGANR3C2HDAC6 | |
| SCHEMBL4582156 | 0.85 | IDH1 (0.46) | NUDT1IDH1OGANR3C2HDAC6 | |
| SCHEMBL4582801 | 0.85 | IDH1 (0.46) | NUDT1IDH1OGANR3C2HDAC6 | |
| SCHEMBL4582161 | 0.85 | IDH1 (0.46) | NUDT1IDH1OGANR3C2HDAC6 | |
| SCHEMBL4582101 | 0.85 | ACHE (0.49) | NUDT1IDH1OGANR3C2HDAC6 | |
| SCHEMBL4582109 | 0.85 | ACHE (0.49) | NUDT1IDH1OGANR3C2HDAC6 | |
| SCHEMBL4580664 | 0.83 | HDAC6 (0.47) | NUDT1IDH1OGANR3C2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323464-B2 | Pyridine and pyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2008-01-29 | — | — | US | claimed |
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | GENTEX CORPORATION | 2005-04-14 | — | — | US | claimed |
| US-7323464-B2 | Pyridine and pyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | GENTEX CORPORATION | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | ROR1, MAPK1, IRAK1 | NUDT1 762/4885IDH1 424/4885OGA 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.